This work was supported by the Council of Scientific and Industrial Research (CSIR) (project title: Comparative Genomics and Biology of Noncoding RNA), India. We also thank Dr. Teena Goel for helping with the in silico docking studies.
The Tuberculosis Drug Streptomycin as a Potential Cancer Therapeutic: Inhibition of miR-21 Function by Directly Targeting Its Precursor†
Article first published online: 15 DEC 2011
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Angewandte Chemie International Edition
Volume 51, Issue 4, pages 1019–1023, January 23, 2012
How to Cite
Bose, D., Jayaraj, G., Suryawanshi, H., Agarwala, P., Pore, S. K., Banerjee, R. and Maiti, S. (2012), The Tuberculosis Drug Streptomycin as a Potential Cancer Therapeutic: Inhibition of miR-21 Function by Directly Targeting Its Precursor. Angew. Chem. Int. Ed., 51: 1019–1023. doi: 10.1002/anie.201106455
- Issue published online: 17 JAN 2012
- Article first published online: 15 DEC 2011
- Manuscript Received: 12 SEP 2011
- Council of Scientific and Industrial Research (CSIR)
Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.